STOCK TITAN
  1. Home
  2. Sec-filings
  3. APLS
  4. [144] Apellis Pharmaceuticals, Inc. SEC Filing

[144] Apellis Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock APLS logo
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

#2316 Ranked by Market Cap
N/A Ranked by Dividends

APLS Latest News

Jul 15, 2025
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Jul 1, 2025
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Jun 6, 2025
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
Jun 4, 2025
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
May 7, 2025
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

APLS Latest SEC Filings

Jul 16, 2025
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity
Jul 15, 2025
[144] Apellis Pharmaceuticals, Inc. SEC Filing
Jul 14, 2025
[144] Apellis Pharmaceuticals, Inc. SEC Filing
Jul 1, 2025
[8-K] Apellis Pharmaceuticals, Inc. Reports Material Event
Jun 20, 2025
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity

APLS Stock Data

2.25B
106.55M
13.86%
103.5%
16.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM